Dissemin is shutting down on January 1st, 2025

Published in

Public Library of Science, PLoS ONE, 4(4), p. e5165, 2009

DOI: 10.1371/journal.pone.0005165

Links

Tools

Export citation

Search in Google Scholar

Insights into Long-Lasting Protection Induced by RTS,S/AS02A Malaria Vaccine: Further Results from a Phase IIb Trial in Mozambican Children

Journal article published in 2009 by Caterina Guinovart, John J. Aponte, Jahit Sacarlal, Pedro Aide, Amanda Leach, Quique Bassat, Eusébio Macete, Carlota Dobaño ORCID, Marc Lievens, Christian Loucq, W. Ripley Ballou, W. Ripley Ballou, Joe Cohen, Pedro L. Alonso
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

The pre-erythrocytic malaria vaccine RTS,S/AS02A has shown to confer protection against clinical malaria for at least 21 months in a trial in Mozambican children. Efficacy varied between different endpoints, such as parasitaemia or clinical malaria; however the underlying mechanisms that determine efficacy and its duration remain unknown. We performed a new, exploratory analysis to explore differences in the duration of protection among participants to better understand the protection afforded by RTS,S.